Fluicell AB (OSTO:FLUI) Total Equity: kr14.21 Mil (As of Mar. 2026)


OSTO:FLUI Fluicell AB OSTO:FLUI
54 GF Score
Price kr30.90
GF Value kr34.58
Valuation Modestly Undervalued
! 4 Warning Signs
View Full Analysis

What is Fluicell AB Total Equity?

Fluicell AB OSTO:FLUI +2.32% 54 Total Equity is kr14.21 Mil as of Mar. 2026. GuruFocus rates OSTO:FLUI with a GF Score™ of 54/100 and a GF Value™ of kr34.58 (Modestly Undervalued). The stock has 4 warning signs investors should review.

Fluicell AB's total equity for the quarter that ended in Mar. 2026 was kr14.21 Mil.

This is Residual interest, including minority interest, that remains in the assets of the enterprise after deducting its liabilities. Equity is increased by owners’ investments and by comprehensive income, and it is reduced by distributions to the owners.

Fluicell AB Total Equity Historical Data

* Premium members only.

The historical data trend for Fluicell AB's Total Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Fluicell AB Total Equity Chart

Fluicell AB Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Total Equity
Get a 7-Day Free Trial Premium Member Only Premium Member Only 19.11 23.45 0.43 19.23 10.90

Fluicell AB Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Total Equity Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 16.56 13.67 10.80 10.90 14.21
OSTO:FLUI
54GF Score
Fluicell AB OSTO:FLUI
Total Equity is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Fluicell AB Total Equity Calculation

Total Equity and Total Liabilities are the two components for Total Assets.

Fluicell AB's Total Equity for the fiscal year that ended in Dec. 2025 is calculated as

Total Equity=Total Assets(Q: Dec. 2025 )-Total Liabilities(Q: Dec. 2025 )
=18.475-7.574
=10.90

Fluicell AB's Total Equity for the quarter that ended in Mar. 2026 is calculated as

Total Equity=Total Assets(Q: Mar. 2026 )-Total Liabilities(Q: Mar. 2026 )
=20.768-6.558
=14.21

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Total Equity →
What does a Total Equity of kr14.21 Mil mean?
Fluicell AB (OSTO:FLUI) has a Total Equity of kr14.21 Mil as of Mar. 2026. The total amount of equity as record on a company's balance sheet. View historical data for Fluicell AB and its competitors.
Is Fluicell AB's Total Equity too high?
Fluicell AB's current Total Equity is kr14.21 Mil. Overall, Fluicell AB has a GF Score™ of 54/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Fluicell AB's Total Equity compare to VRTX and REGN?
Fluicell AB's Total Equity of kr14.21 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Equity for a Biotechnology company?
A good Total Equity depends on the Biotechnology industry context. However, Total Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Equity mean?
A high Total Equity can signal that a stock is expensive relative to its fundamentals. The total amount of equity as record on a company's balance sheet. View historical data for Fluicell AB and its competitors. Fluicell AB's current Total Equity is kr14.21 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Fluicell AB stock overvalued right now?
Based on GuruFocus' analysis, Fluicell AB (OSTO:FLUI) is currently considered Modestly Undervalued. The stock's GF Value™ is kr34.58, compared to a current price of kr30.90 — trading 10.6% below its estimated fair value. The current Total Equity is kr14.21 Mil. Fluicell AB's overall GF Score™ is 54/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Equity calculated?
Total Equity is calculated from a company's financial statements. For Fluicell AB (OSTO:FLUI), the current Total Equity is kr14.21 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Fluicell AB (OSTO:FLUI) Overvalued in 2026?

Based on GuruFocus' analysis, Fluicell AB stock appears to be undervalued. The current stock price of kr30.90 is trading 10.6% below its estimated GF Value™ of kr34.58. GuruFocus considers Fluicell AB to be Modestly Undervalued.

Key valuation signals for OSTO:FLUI:

  • Total Equity: kr14.21 Mil
  • GF Value™: kr34.58 vs. price of kr30.90 (10.6% below fair value)
  • GF Score™: 54/100 with 4 warning signs

No single metric tells the full story. See the OSTO:FLUI stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Fluicell AB Business Description

Other Exchanges 5J90:Germany
Address Flojelbergsgatan 8C, Molndal, Gothenburg, SWE, 431 37
Fluicell AB is a Swedish life science company that conducts development in regenerative medicine and human tissue-based screening models for drug development, with a particular focus on the areas of type 1 diabetes, cardiac safety screening models, and kidney diseases. The company's platform for the production of human tissue that is based on Fluicell's technology for high-resolution 3D bioprinting, and which enables the creation of tissue-based products for use in drug development and regenerative medicine.
54GF Score

Get the complete analysis for OSTO:FLUI

Total Equity is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

kr30.90
Price
kr34.58
GF Value